Tioconazole

Tioconazole (UK-20349) is a broad-spectrum antifungal imidazole derivative. Tioconazole inhibits several dermatophytes and yeasts, with MIC₅₀ values of less than 3.12 mg/L and 9 mg/L, respectively. Additionally, Tioconazole exhibits anti-parasitic activity. Tioconazole exerts anticancer activity by inhibiting the PI3K/AKT/mTOR signaling pathway and blocking autophagy. Tioconazole is applicable for research in the fields of anti-infection and anticancer therapy^{[1][2][3][4][5]}. IC50 & Target:Antifungal^[1]. In Vitro:Tioconazole (10-40 μM, 24 hours) induces apoptosis and inhibits cell migration in HeLa cells through mitotic arrest, exhibiting anticancer activity (IC₅₀: 14.9 μM)^[3]. In Vivo:Tioconazole (60 mg/kg, i.p., once every 3 days for 43 days) in combination with Doxorubicin (HY-15142) (5 mg/kg) and Chloroquine (HY-17589A) (50 mg/kg) exerts anti-tumor effects in the MCF-7 cell xenograft breast cancer BALB/c mouse model by inhibiting the PI3K/AKT/mTOR signaling pathway and blocking autophagy^[4].
Tioconazole (60 mg/kg, i.p., once every other day for 21 days) enhances the anti-tumor effects of Dox in the HCT116 cell xenograft colorectal cancer nude mouse model^[5].